Naya Therapeutics Inc. is expanding its hepatocellular carcinoma pipeline with the addition of NY-700, a first-in-class GPC3-targeted Astatine-211 (211At) α radioimmunotherapy aiming to address residual disease, micro-metastasis and post-immunotherapy failures.
Sunrock Biopharma SL and Shanghai Escugen Biotechnology Co. Ltd. have joined forces in a strategic partnership to codevelop SRB-123, a first-in-class antibody-drug conjugate (ADC) targeting C-C motif chemokine receptor 9 (CCR9), a tumor-associated antigen overexpressed in multiple solid tumors, including pancreatic, ovarian and lung cancer.
Opioid use disorder (OUD) remains a significant public health crisis, with over 5 million people diagnosed in the U.S. in 2023 and more than 80,000 fatal overdoses involving opioids each year. Current FDA-approved medications for OUD target the micro-opioid receptor, but these treatments are still associated with high relapse rates during abstinence.
Among the presentations included in the Top Abstracts category at the recently inaugurated Annual Congress of the European Association for Cancer Research (EACR) in Lisbon, it is worth highlighting two that respectively addressed the role of cytokines and lipid-sensing receptors as key modulators of the tumor microenvironment, a central theme in current cancer research.
Chinese researchers are preparing the details for the publication of another scientific milestone, the creation of a chimera with a human heart and a kidney developed from human stem cells in pig embryos. These studies aim to address the shortage of immunocompatible organ donors while shedding light on some of the most fundamental questions in developmental biology.
Ascletis Pharma (China) Co. Ltd. has described glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH), diabetes, obesity, metabolic syndrome and more.
Ariel Scientific Innovations Ltd. has identified dolastatin 10 analogues and its conjugates comprising another functional moiety and a linking moiety reported to be useful for the treatment of cancer.
University of Sydney has synthesized translocator protein (TSPO; PBR) (A147T mutant) ligands reported to be useful for the diagnosis and treatment of neurological disorders.
Biogen Inc. has disclosed huntingtin (HTT; HD) (mutant) splicing modulators reported to be useful for the treatment of Huntington’s disease and spinal muscular atrophy (SMA).
RSS
